Open AccessRelapsed or primary refractory AML
Author(s) -
Kristin Koenig,
Alice S. Mims
Publication year - 2020
Publication title -
current opinion in hematology/current opinion in hematology, with evaluated medline
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 97
eISSN - 1080-8213
pISSN - 1065-6251
DOI - 10.1097/moh.0000000000000561
Subject(s) - refractory (planetary science) , medicine , salvage therapy , chemotherapy , oncology , myeloid leukemia , physics , astrobiology
Treatment of relapsed and refractory acute myeloid leukemia (AML) is still very challenging, with poor response rates and low chance for cure. This is especially true when treating patients who are elderly, have multiple comorbidities, or who are too unfit for traditional salvage chemotherapy regimens.